Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome

Blood Purification

Volumn 27, Issue 1, 2009, Pages 28-32

  Schrier, Robert W ^a,b   Masoumi, Amirali ^a   Elhassan, Elwaleed ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Antidiuretic hormone; Heart failure; Hyponatremia; Kidney function

Indexed keywords

CLOTIAZEPAM; CONIVAPTAN; CREATININE; LOOP DIURETIC AGENT; SODIUM; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; WATER;

CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; HEART AFTERLOAD; HEART FAILURE; HUMAN; HYPONATREMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER CIRRHOSIS; LUNG CONGESTION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; POLYDIPSIA; PRIORITY JOURNAL; SODIUM RETENTION; VASOCONSTRICTION; WATER RETENTION;

BENZAZEPINES; HEART FAILURE; HUMANS; HYPONATREMIA; KIDNEY; KIDNEY DISEASES; RECEPTORS, VASOPRESSIN; VASOPRESSINS;

EID: 58849148503     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167005     Document Type: Conference Paper

References (29)

1. Gheorghiade M, Gattis W, Klein L: OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization. Eur J Heart Fail 2003;5:9-12.
2. Dries D, Exner D, Domanski M, Greenberg B, Stevenson L: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689.
3. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
4. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1839-1906.
6. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann L, Druml W, Bauer P, Hiesmayr M: Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004;15:1597-1605.
7. Schrier RW: Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006;47:1-8.
8. Schrier RW: Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007;3:637.
9. Ronco C, House AA, Haapio M: Cardiorenal and renocardiac syndromes: the need for a comprehensive classification and consensus. Nat Clin Pract Nephrol 2008;4:310-311.
10. Ronco C, House AA, Haapio M: Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008;34:957-962.
11. Ronco C, et al: Cardiorenal syndrome. J Am Coll Cardiol, in press.
12. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma and norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
13. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(6 suppl):VI40-VI48.
14. Lee WH, Packer M: Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-267.
15. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet BG, Berl T, Schrier RW: Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-266.
16. Funayama H, Nakamura T, Saito T, Yoshimura A, Saito M, Kawakami M, Ishikawa SE: Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 2004;66:1387-1392.
17. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper M: Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82:205-244.
18. Bichet DG, Kortas C, Mettauer B, Manzini C, Marc-Aurele J, Rouleau JL, Schrier RW: Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 1986;29:1188-1196.
19. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; for the SALT Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112.
20. Martin PY, Abraham WT, Leiming X, Olson BR, Oren R, Ohara M, Schrier RW: Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999;10:2165-2170.
21. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-585.
22. Schrier RW, Abdallah J, Weinberger H, Abraham W: Therapy of heart failure. Kidney Int 2000;57:1418-1425.
23. Daughty RN, Rodgers A, Sharpe N, MacMahon S: Effects of beta-blocker therapy in mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-567.
24. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Geb H, Wong M: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991;325:30-310.
25. Garg R, Yusuf S; the Collaborative Group on ACE Inhibition Trials: Overview of randomized trials of angiotensin-converting enzymes inhibitors in patients with heart failure. JAMA 1995;273:1450-1457.
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
27. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331.
28. Klein L, Massie B, Leimberger J, O'Connor C, Piña I, Adams I Jr, Califf R, Gheorghiade M; for the OPTIME-CHF Investigators: Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008;1:25-33.
29. Schrier RW: Blood urea nitrogen (BUN) and serum creatinine: Not married in heart failure. Circ Heart Fail 2008;1:2-5.